Actively Recruiting
Venous Thromboembolism Prevention in Outpatients With Glioma
Led by University of Vermont Medical Center · Updated on 2026-01-30
40
Participants Needed
1
Research Sites
232 weeks
Total Duration
On this page
Sponsors
U
University of Vermont Medical Center
Lead Sponsor
D
Dartmouth-Hitchcock Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
CONDITIONS
Official Title
Venous Thromboembolism Prevention in Outpatients With Glioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection
- Age 18 and old
- Karnofsky performance status (KPS) 60-100
- Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25
- Ability to provide informed consent
- Planning for treatment with radiation and chemotherapy
You will not qualify if you...
- Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment
- Pregnancy
- Significant bleeding risk including history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial trauma in the past 6 months, including stroke or traumatic brain injury, major surgery or major procedure within 48 hours
- Allergy to apixaban or contraindication to prophylactic anticoagulation including current use of unfractionated heparin, low molecular weight heparin, heparin derivatives, or other direct oral anticoagulants which cannot be stopped
- Use of strong CYP3A4 inhibitors and P-glycoprotein inhibitors
- Indication for full anticoagulation such as atrial fibrillation or mechanical valve
- Estimated life expectancy of less than 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Vermont Medical Center
Burlington, Vermont, United States, 05401
Actively Recruiting
Research Team
A
Alissa A Thomas, MD
CONTACT
D
Donna Silver
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here